175 related articles for article (PubMed ID: 25671833)
1. Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics.
Schaeffer S; Khalili M
Ann Hepatol; 2015; 14(2):234-42. PubMed ID: 25671833
[TBL] [Abstract][Full Text] [Related]
2. Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans.
Beck KR; Kim NJ; Khalili M
Ann Hepatol; 2018; 17(3):413-418. PubMed ID: 29735789
[TBL] [Abstract][Full Text] [Related]
3. Racial Disparities in Hepatitis C Treatment Eligibility.
Sims OT; Pollio DE; Hong BA; North CS
Ann Hepatol; 2017; 16(4):530-537. PubMed ID: 28611273
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C in African Americans.
Saab S; Jackson C; Nieto J; Francois F
Am J Gastroenterol; 2014 Oct; 109(10):1576-84; quiz 1575, 1585. PubMed ID: 25178700
[TBL] [Abstract][Full Text] [Related]
5. Race and Hepatitis C Care Continuum in an Underserved Birth Cohort.
Kim NJ; Locke CJ; Park H; Magee C; Bacchetti P; Khalili M
J Gen Intern Med; 2019 Oct; 34(10):2005-2013. PubMed ID: 30238404
[TBL] [Abstract][Full Text] [Related]
6. Determinants of Treatment Eligibility in Veterans With Hepatitis C Viral Infection.
Taylor J; Carr-Lopez S; Robinson A; Malmstrom R; Duncan K; Maniar A; Re ACD; Carmichael JM
Clin Ther; 2017 Jan; 39(1):130-137. PubMed ID: 27989619
[TBL] [Abstract][Full Text] [Related]
7. Racial differences in hepatitis C treatment eligibility.
Melia MT; Muir AJ; McCone J; Shiffman ML; King JW; Herrine SK; Galler GW; Bloomer JR; Nunes FA; Brown KA; Mullen KD; Ravendhran N; Ghalib RH; Boparai N; Jiang R; Noviello S; Brass CA; Albrecht JK; McHutchison JG; Sulkowski MS;
Hepatology; 2011 Jul; 54(1):70-8. PubMed ID: 21488082
[TBL] [Abstract][Full Text] [Related]
8. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment.
Penberthy L; Brown R; Wilson-Genderson M; Dahman B; Ginder G; Siminoff LA
Clin Trials; 2012 Dec; 9(6):788-97. PubMed ID: 23033547
[TBL] [Abstract][Full Text] [Related]
9. Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C.
Liu L; Daftary MN; Alzahrani MS; Ohanele C; Maneno MK
J Natl Med Assoc; 2021 Apr; 113(2):147-157. PubMed ID: 32868101
[TBL] [Abstract][Full Text] [Related]
10. Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons.
Thompson VV; Ragland KE; Hall CS; Morgan M; Bangsberg DR
AIDS; 2005 Oct; 19 Suppl 3():S208-14. PubMed ID: 16251820
[TBL] [Abstract][Full Text] [Related]
11. Ethnic epidemiological profiles and antiviral therapy among patients infected with hepatitis C virus genotype 4: a multicenter study from Belgium.
Nkuize M; Mulkay JP; Moreno C; Lasser L; Michielsen P; de Galocsy C; Scheen R; Assene C; Delwaide J
Acta Gastroenterol Belg; 2015 Dec; 78(4):365-72. PubMed ID: 26712045
[TBL] [Abstract][Full Text] [Related]
12. Short article: Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
Sims OT; Guo Y; Shoreibah MG; Venkata K; Fitzmorris P; Kommineni V; Romano J; Massoud OI
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1219-1222. PubMed ID: 28857899
[TBL] [Abstract][Full Text] [Related]
13. Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment.
Batki SL; Canfield KM; Ploutz-Snyder R
Am J Addict; 2011; 20(4):312-8. PubMed ID: 21679262
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C Virus Infection Outcomes Among Immigrants to Canada: A Retrospective Cohort Analysis.
Cooper CL; Thavorn K; Damian E; Corsi DJ
Ann Hepatol; 2017; 16(5):720-726. PubMed ID: 28809741
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.
Evon DM; Simpson K; Kixmiller S; Galanko J; Dougherty K; Golin C; Fried MW
Am J Gastroenterol; 2011 Oct; 106(10):1777-86. PubMed ID: 21769136
[TBL] [Abstract][Full Text] [Related]
16. Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure.
Spradling PR; Zhong Y; Moorman AC; Rupp LB; Lu M; Gordon SC; Teshale EH; Schmidt MA; Daida YG; Boscarino JA;
Hepatol Commun; 2021 Mar; 5(3):400-411. PubMed ID: 33681675
[TBL] [Abstract][Full Text] [Related]
17. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.
Chainuvati S; Khalid SK; Kancir S; Shea M; Edwards J; Sernyak M; Wongcharatrawee S; Garcia-Tsao G
J Viral Hepat; 2006 Apr; 13(4):235-41. PubMed ID: 16611189
[TBL] [Abstract][Full Text] [Related]
18. Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection.
Livingston SE; Townshend-Bulson LJ; Bruden DL; McMahon BJ; Homan CE; Gove JE; Deubner H; Bruce MG; Robinson RF; Gretch DR
Int J Circumpolar Health; 2012 Apr; 71():1-7. PubMed ID: 22564468
[TBL] [Abstract][Full Text] [Related]
19. Disparities in hepatitis C virus infection screening among Baby Boomers in the United States.
Nili M; Luo L; Feng X; Chang J; Tan X
Am J Infect Control; 2018 Dec; 46(12):1341-1347. PubMed ID: 30017311
[TBL] [Abstract][Full Text] [Related]
20. Influence of female sex on hepatitis C virus infection progression and treatment outcomes.
Corsi DJ; Karges W; Thavorn K; Crawley AM; Cooper CL
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):405-11. PubMed ID: 26745470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
